Abraxane in Treatment of Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2016-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This observational project is collecting tolerability, safety and efficacy data with the routine use of Abraxane in the treatment of metastatic breast cancer. Additionally data on the dosage of Abraxane and general data on the disease and the health status of the patient will be collected.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene; Celgene Corporation
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

1. Patients with metastatic breast cancer (according to European Summary of Product characteristics (SmPC)

2. Signed Informed Consent

3. Participants > 18 Years of Age

Exclusion Criteria:

1. Pregnant or lactating females

2. Neutrophils <1.5 X 10^9/L

3. Hypersensivity to nab-paclitaxel